Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases


The purpose of this study was to determine the safety and therapeutic effect of sub-retinal transplantation of human embryo stem cell derived retinal pigment epitheliums (hESC-RPE) in patients with macular degeneration diseases, and explore new treatment modalities for macular degeneration diseases (Age-related macular degeneration and Stargardt's macular dystrophy).

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2018


  • Procedure: Subretinal transplantation
    • Transplant hESC-RPE into subretinal space of patients with macular degeneration

Arms, Groups and Cohorts

  • Experimental: hESC-RPE
    • Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums

Clinical Trial Outcome Measures

Primary Measures

  • Number of participants with Treatment-Related Adverse Events [Safety and Tolerability]
    • Time Frame: up to 12 months
    • Patients with Treatment-Related Adverse Events caused by local rejection of implanted cells or systemic immunosuppression treatment

Secondary Measures

  • Number of Early Treatment Diabetic Retinopathy (ETDR ) letters participants can recognize
    • Time Frame: up to 12 months
    • Visual acuity is reflected by number of ETDR letters participants can recognize
  • Visual Field as examined by Static perimetry
    • Time Frame: up to 12 months
    • Area and sensitivity of visual field are detected by Static perimetry
  • Flash Electroretinogram (FERG)
    • Time Frame: up to 12 months
    • Retinal electrophysiological function is tested by FERG
  • Amplitude and Latency of Flash Visual Evoked Potentials (FVEP)
    • Time Frame: up to 12 months
    • Optic nerve function as assessed by FVEP
  • Multifocal Electroretinogram (MFERG)
    • Time Frame: up to 12 months
    • Local retinal function as assessed by MFERG

Participating in This Clinical Trial

Inclusion Criteria

  • Aging from 18 to 75 years
  • must have signed informed consent
  • At least one visually impaired eye caused by macular degeneration diseases
  • Can not be effectively treated with conventional therapies
  • Best corrected visual acuity scores between 19 and 73 letter in ETDRs (early treatment diabetic retinopathy ) eye chart , including 19 and 73 (or the equivalent of Snellen eyesight from 20/400 to 20/40)
  • Visual loss caused by macular degeneration diseases

Exclusion Criteria

  • Eyes with concomitant diseases which will interfere the visual improvement of the study
  • Active intraocular inflammation regardless of the grade of severity
  • Active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, ophthalmia)
  • History of uveitis
  • Severe cataract, glaucoma, retinal blood vessels occlusion, retinal detachment, macular hole, vitreous-macula traction
  • Iris neovascularization
  • Patients who have only one functioning eye, or the best corrected vision of untreated eye scores less than 24 letters in ETDRS chart(corresponding to 20/320 in Snellen chart)
  • History of intraocular surgery
  • Severe systemic diseases: Stroke, coronary heart disease, angina pectoris, renal insufficiency needing dialysis
  • Allergic to sodium fluorescein
  • Uncontrolled hypertension (systolic pressure>140mmHg,or diastolic pressure>90mmHg)
  • Coagulative function disorder
  • System administration of drugs that are toxic to lens, retina, or optic nerve like hydroxychloroquine, phenothiazine, ethambutol, tamoxifen, etc.
  • Involved in other clinical trials of any medicine within 1 month (or within 5 half-life periods)
  • Have maternity plan in 6 months
  • In pregnancy or lactation period.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Southwest Hospital, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: ZhengQin Yin, Professor – Southwest Hospital, China

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.